2010-08-31 05:01:02 -
Research and Markets ( www.researchandmarkets.com/research/919418/pharmaceutical_ma : 
) has announced the addition of the "Pharmaceutical M&A in the Asia-Pacific Region - India and China Drive Regional Activity but Japan Still Dominates High Value Transactions" report to their offering.
Expanding healthcare coverage in emerging Asia-Pacific markets, rapid economic growth and burgeoning middle classes are attracting foreign M&A as companies attempt to offset future losses from the looming threat of the 2011 patent cliff and slowing growth in major developed markets. As these markets develop, consolidation of the domestic industry is also driving M&A in the Asia-Pacific region.
Scope
- Provides an overview of the healthcare systems and pharmaceutical markets of key countries within Asia-Pacific.
- Overview of drivers, resistors and trends within
the Asia-Pacific M&A landscape.
- Analysis of the types of acquisitions and healthcare sectors targeted.
- Analysis of geographic M&A activity and transaction values.
Highlights of this title
Sluggish performance in the major pharmaceutical markets prompted by growing generic competition and increasing healthcare cost-containment are forcing companies to seek opportunities elsewhere. Massive populations, rapid economic growth and burgeoning middle classes make emerging Asia-Pacific markets particularly attractive to foreign companies.
Companies penetrating these markets often acquire local manufacturers and generics firms that provide a quick, cost-effective point of entry from which to later launch more expensive branded products. However, some Asia-Pacific countries are introducing or considering measures to protect the domestic industries from foreign domination.
Within the period analyzed in this report, the highest number of M&A deals involving APAC based companies was recorded in 2008. Strong recovery from the global financial crisis can be seen in late 2009.
Furthermore, 2010 seems to be off to a good start, with a number of large deals involving APAC-based companies having been announced.
Key reasons to purchase this title
- Gain insight into the number and scope of M&A transactions in Asia-Pacific, and key drivers and resistors.
- Identify which are the most perused pharmaceutical sectors in terms of M&A deals, and which companies have been the most acquisitive in recent years.
- Identify which markets have been most frequently targeted through M&As, and which have attracted the attention of Big Pharma.
Key Topics Covered:
1. Executive Summary
2. Overview of the APAC pharmaceutical markets
3. Overview of M&A activity
4. Country specific M&A activity
5. Bibliography
For more information visit
www.researchandmarkets.com/research/919418/pharmaceutical_ma :
.
Source: Datamonitor
Research and MarketsLaura Wood, Senior Manager,
press@researchandmarkets.com : mailto:press@researchandmarkets.com U.S.
Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716
